Another US Food and Drug Administration-approved CAR-T cell-based therapy that targets B cell tumor antigens is B cell maturation antigen (BCMA)-specific CAR-T cells, which are approved for treating multiple myeloma. Here, TNFRSF17 is linked to plasma cell myeloma.